A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
about
Oligonucleotide therapeutic approaches for Huntington diseaseTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's DiseaseTemporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutationTherapeutic prospects for spinocerebellar ataxia type 2 and 3.Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophyDetection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules.Modeling Huntington disease in yeast: perspectives and future directions.Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitorsA small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's diseaseSystemic delivery of P42 peptide: a new weapon to fight Huntington's disease.Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 miceHuntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxiasIron accumulates in Huntington's disease neurons: protection by deferoxamineNeonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.Huntington's Disease and Striatal Signaling.The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease modelThiol-disulfide Oxidoreductases TRX1 and TMX3 Decrease Neuronal Atrophy in a Lentiviral Mouse Model of Huntington's DiseaseStriatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease modelsNeuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.Neuroprotection for Huntington's disease: ready, set, slowNeurobiological applications of small molecule screening.Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders.A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation.Protein aggregates in Huntington's disease.scyllo-Inositol promotes robust mutant Huntingtin protein degradation.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Using Drosophila models of neurodegenerative diseases for drug discovery.Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
P2860
Q22306293-2A6F6A5D-52C9-4D64-A9DC-EBA17317B9BDQ24289511-532D9A8F-E265-49E3-9BAE-0E7375309F90Q27005950-AEE59E1E-7CF6-4F36-962B-1A8E36E7E8C5Q27022757-BC5B43A4-FCDE-4118-8A0F-1975767952B3Q28728849-15090B73-0568-4069-A47A-DB94053B180BQ30410969-B59DB0BE-43C5-4F24-8C0F-6E385BEBA0A8Q30492560-3D9807ED-35BC-457F-B7A5-51153DCF3567Q30547549-322EBFB8-E42E-4496-9EC4-F87BE401F296Q33575494-6EB2C246-8AFC-4616-A93E-E82ECE9A4404Q33603921-2888C6F5-A5EE-4757-9A38-D82C1EABE9FAQ33640604-B534F9BB-7491-4580-B653-35456E31640CQ34011801-197F2207-6428-4415-A99A-E0CE4BFBA187Q34013257-E410C016-999D-416E-AE3D-E0FC76A90107Q34109060-9212EFD9-F04D-46E3-9783-29E2B8016EDCQ34459323-9D7D1820-FDA7-4A4E-B9F3-0A54F2000073Q34797845-446B8AAE-132C-44A7-B6AC-402BD7E97C68Q34981549-5DC0704A-1024-4E0B-B17A-3BE1DC9DE5BEQ35023030-DC9150B1-A31F-41D3-87B8-71FB1B34188CQ35143644-AEC1923F-7B20-4EAE-A1AC-11D60ACD5F4CQ35161675-4AEE7CA7-4F87-4E19-BD0C-B61FDDD7BA09Q35244160-E7822CFE-3BB7-401C-A532-2E47A9CD2C6CQ35286098-B6F52EE9-C82D-4A66-AD69-DE675BD9BA8CQ35542836-1187299C-D285-4F2B-ABAF-B99ACFF93A6EQ35748307-83352998-80F1-4B8E-9068-2883542726FBQ35868172-734EB5FD-C0D7-4423-BFCB-4DE13DF130B6Q35871006-4A16B5A7-9BC0-443F-90F2-261124BC7AAAQ36501584-AC798896-32E2-499B-AF10-A21EC32FAB34Q36538885-AA2DCD09-0D40-48F3-AE71-C6942319A264Q36813115-BE52FA2F-ED0F-4A13-85F5-66BF148EDA69Q37131243-3D178F81-8D2F-4D28-9C28-C87FA80C8FC3Q37151213-B767DF01-C91C-4B39-B5D4-1B9296141168Q37201299-4A7268CF-FF3F-4F9F-9156-C3DC53B6789BQ37345118-BCE57008-1E18-4A72-8973-5DF76BFA9E88Q37482190-D1C2C97C-C1C4-4321-980D-4F386034660FQ37540988-7EE0EF97-8CF7-45C6-8455-08E0FB142926Q37563551-69992630-256B-473B-B53D-E1CAAE49BB4CQ37776087-55D18F24-EAF9-4C94-B00F-A194B73F8888Q38014579-E17519EB-F43F-4E45-842F-EB87E0FD5A49Q38108756-DCC4E3CB-0A70-45A3-87D4-7C15A2A1EFB1Q38160307-7A7E6609-0444-4C20-BFF9-B26C77B88EAD
P2860
A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@ast
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@en
type
label
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@ast
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@en
prefLabel
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@ast
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@en
P2093
P2860
P356
P1476
A small-molecule therapeutic l ...... in the R6/2 transgenic mouse.
@en
P2093
Aleksey Kazantsev
Anne B Young
David E Housman
Greg Lieberman
Jonathan H Fox
Kathryn Dorsey
Peter Waldmeier
Vanita Chopra
Wayne Matson
P2860
P304
16685-16689
P356
10.1073/PNAS.0707842104
P407
P577
2007-10-09T00:00:00Z